675 articles in this topic
A newly discovered phage-fibroblast-B cell circuit explains how chronic stress drives tumor growth by suppressing anti-tumor immunity.
Researchers discovered why fibrolamellar carcinoma resists immunotherapy and found an existing drug can free trapped T cells to fight it.
A completed phase 3 trial compared A+AVD versus ABVD for advanced classical Hodgkin lymphoma, testing whether replacing bleomycin with brentuximab vedotin improves outcomes.
A clinical trial shows 4g/day icosapent ethyl nearly tripled marine omega-3 content in colorectal tissue, shifting the omega-3/omega-6 ratio favorably.
Phase 1 trial evaluates PF-06863135 (elranatamab) alone and with immunomodulatory agents to find safe dosing in heavily pretreated myeloma patients.
A ddPCR assay targeting methylated ctDNA detects sarcoma in blood with 74% sensitivity and predicts treatment outcomes.
Scientists expand granulocyte-monocyte progenitors into a scalable CAR platform that infiltrates tumors and fights leukemia and solid cancers.
MD Anderson researchers reveal a feedback loop between cuproptosis and CD8+ T cells that could unlock new combination therapies for immune-resistant tumors.
A novel liquid biopsy scoring tool called MinerVa-Delta predicted survival in advanced lung cancer with striking accuracy, even when imaging was ambiguous.
Fate-AI integrates DNA fragmentation and methylation signals to detect 10 cancer types from blood with AUCs up to 0.97.
Targeting a single protein in immune cells rewires cholesterol metabolism to flip immunosuppressive macrophages into tumor-fighting ones.
New review from Nature Cancer reveals how immune-organizing structures inside tumors could predict and enhance immunotherapy response.
